

# Generation of tumor-reactive T cells

# CliniMACS Prodigy® Tumor Reactive T Cell Process

### **Application**

Fully automated stimulation, labelling, enrichment, activation, transduction, and expansion of human T cells from patient material (either derived from tumor or via leukapheresis) for the production of tumor-reactive T cells.

This application sheet gives an overview of the specifications and materials required to perform the Tumor Reactive T Cell (TRT) Process on the CliniMACS Prodigy. In addition, it illustrates the process workflow and tubing set configuration, and provides performance data of our own in-house results.

#### **Specifications**

•	
Process name:	Tumor Reactive T Cell Process
Starting cell number for stimulation/ selection:	Tumor digest: up to $2-4\times10^8$ Leukapheresis: up to $1\times10^9$
Starting cell number for expansion:	Up to 1×10 <sup>7</sup> (recommended 1×10 <sup>6</sup> )
Sample volume for selection:	20–200 mL
Final cell product volume:	100 mL
Process time:	12–15 days

### Material required

CliniMACS® Materials	Amount required		
CliniMACS Prodigy	1 unit		
CliniMACS Prodigy TS 520	1 piece		
CliniMACS PBS/EDTA Buffer	1×3 L		
CliniMACS PBS/EDTA Buffer	1×1 L		
CliniMACS CD137 GMP Biotin	1 vial		
CliniMACS Anti-Biotin GMP MicroBeads	1 vial		
TexMACS™ GMP Medium (2 L bag)	~3×2 L bag		
MACS® GMP CD3 pure	1 vial		
MACS GMP Recombinant Human IL-2 (500 $\mu$ g)	~4-8 vials		
MACS GMP Vectofusin®-1	Variable		

Additional materials	Amount required		
Luer/Spike Interconnector	Variable		
Triple sampling adapter	Variable		
20 mL Reagent Bag	1–2 pieces		
Human serum albumin (HSA)	Variable		
Human AB serum	Variable		
Sterile water for injection	Variable		
Viral vector	Variable		
Formulation solution	Variable		
150 mL Transfer Bags	Variable		
Syringes	Variable		
Uninterruptable power supply	Presumed on site		
CO <sub>2</sub> and compressed air supply	Presumed on site		
Sterile tubing welder	Presumed on site		
Device to measure glucose and lactate levels	Presumed on site		
Flow cytometer, e.g., MACSQuant® Analyzer 10 / Cell counter	Presumed on site		
X-ray device for preparation of feeder cells	Presumed on site		


1

### Process overview

	Tubing set installation and priming				
Pre-process	▼ · · · · · · · · · · · · · · · · · · ·				
	Connection of starting material to tubing set				
	▼ · · · · · · · · · · · · · · · · · · ·				
	LP: Peptides (+ cytokines)				
Stimulation	Tumor: Tumor digest (+ peptides/cytokines)				
	<b>▼</b>				
T cell enrichment	CD137 <sup>+</sup> T cell enrichment				
	▼ ·				
	Feeder cells (Irradiated LP or PBMCs) addition MACS GMP CD3 pure				
Activation	<b>▼</b>				
Outional transduction	Lentiviral transduction (+ MACS GMP Vectofusin®-1)				
Optional transduction	▼ ·				
Cell expansion	Expansion in TexMACS Medium with IL-2				
Cell expansion	▼ ·				
Call beautiful Carl Carl	Cells wash and harvest in 100 mL of buffer				
Cell harvest and final formulation	<b>▼</b>				
Post-process	Tubing Set de-installation				

12-15 days

## CliniMACS Prodigy TS 520 setup for the Tumor Reactive T Cell Process



#### Performance data

_	Starting product CD137 <sup>+</sup> labeled cells (%)	Isolated CD137 <sup>+</sup> cells (%)		CD3 <sup>+</sup> T cells (%)	CD4 <sup>+</sup> /CD8 <sup>+</sup> T cells (%)	Viability (%)	Fold expansion	T cell number (×10 <sup>6</sup> )
MEL 1	20.1	95.3	58.1	98.4	25.1 / 73.1	98.8	80,556	1,450
MEL 2	23.8	97.1	41.3	73.8	40.0 / 16.3	96.8	131	2.63
LP 3	4.9	89.2	22.2	97.2	37.8 / 56.3	99.3	5,300	5,300
LP 4	7.6	88.7	36.7	98.2	18.9 / 74.7	98.8	3,769	5,676

**Table 1:** Isolation of tumor-reactive T cells derived from patient material (frozen melanoma digests, MEL) and healthy donor leukapheresis material stimulated with peptides (LP). In-house data.



**Miltenyi Biotec B.V. & Co. KG** | Phone +49 2204 8306-0 | Fax +49 2204 85197 | macsde@miltenyi.com | **www.miltenyibiotec.com**Miltenyi Biotec provides products and services worldwide. Visit **www.miltenyibiotec.com/local** to find your nearest Miltenyi Biotec contact.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. MACS GMP Products are for research use and ex vivo cell culture processing only, and are not intended for human in vivo applications. For regulatory status in the USA, please contact your local representative. MACS GMP Products are manufactured and tested under a quality system certified to ISO 13485 and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials. The CliniMACS System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.

In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for *in vitro* use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans, the national legislation and regulations – e.g. for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") – must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.

In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved as a Humanitarian Use Device (HUD), authorized by U.S. Federal law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this indication has not been demonstrated. Other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application, Investigational Device Exemption (IDE) or FDA approval. CliniMACS GMP MicroBeads are for research use and ex vivo cell processing only. CliniMACS, CliniMACS Prodigy, MACS, MACSQuant, TexMACS, Vectofusin and the Miltenyi Biotec logo are registered trademarks or trademarks of Miltenyi Biotec and/or its affiliates in various countries worldwide. Copyright © 2022 Miltenyi Biotec and/or its affiliates. All rights reserved.